---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-24-000046"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:22:34.597274+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Travere reports Q3 net loss $54.8M; FILSPARI sales $35.6M, full FDA approval in IgAN

## Summary
- Net product sales $61.0M (FILSPARI $35.6M); 505 new PSFs in Q3; 2,989 total since launch.
- Full FDA approval for FILSPARI in IgAN on Sept 5, 2024; broader label and orphan exclusivity to 2031.
- R&D $51.7M, SG&A $65.6M; net loss $54.8M ($0.70/share); cash $277.4M.
- sNDA submitted to modify liver monitoring; Type C meeting with FDA scheduled for FSGS path.
- Voluntary halt of enrollment in Phase 3 HARMONY (pegtibatinase) due to manufacturing scale-up; restart expected 2026.

## SEC filing metadata
- accession: 0001438533-24-000046
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853324000046/0001438533-24-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853324000046/tvtx-20241031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-24-000046
- JSON: https://secwatch.observer/filing/0001438533-24-000046.json
- Plain text: https://secwatch.observer/filing/0001438533-24-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.